Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PEGylated haemoglobin and carbon monoxide - Prolong Pharmaceuticals

Drug Profile

PEGylated haemoglobin and carbon monoxide - Prolong Pharmaceuticals

Alternative Names: PEG haemoglobin; PEG haemoglobin carbon monoxide; PEG-bHb-CO; PEG-COHb; PEG-haemoglobin-CO; PEG-Hb; PEG-LEH; Pegylated carboxyhemoglobin bovine; Pegylated haemoglobin carbon monoxide; Polyethylene glycol modified bovine haemoglobin; PP 007 -Prolong Pharmaceuticals; Sanguinate

Latest Information Update: 06 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Enzon Pharmaceuticals; Rutgers
  • Developer Prolong Pharmaceuticals
  • Class Anti-ischaemics; Antifibrotics; Haemoglobins; Polyethylene glycols; Recombinant proteins; Vascular disorder therapies
  • Mechanism of Action Oxygen carriers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Delayed graft function
  • Phase II Cerebral ischaemia; Stroke; Vaso-occlusive crisis
  • Preclinical Cystic fibrosis
  • No development reported Beta-thalassaemia

Most Recent Events

  • 09 Feb 2023 Pharmacodynamics data from preclinical studies in Stroke released by Prolong Pharmaceuticals
  • 22 Nov 2022 Preclinical trials in Cystic fibrosis in USA (unspecified route) Before November 2022 (Prolong Pharmaceuticals pipeline, November 2022)
  • 28 Jan 2022 No recent reports of development identified for clinical-Phase-Unknown development in Beta-thalassaemia in USA (Parenteral)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top